This site is intended for healthcare professionals outside the U.S.
|Studya||Total number of|
|Clinical Trials in PsA|
|Clinical Trials in PsO|
PALACE 1, 2, and 3 were multicenter, randomized, double-blind, placebo-controlled phase 3 trials of similar design3
In these trials, all patients were required to have been treated with small-molecule and/or biological DMARD(s). These trials had a similar design:
Patients received OTEZLA as monotherapy but were allowed to continue on stable doses of oral corticosteroids and/or NSAIDs or narcotic analgesic.
DMARD, disease-modifying antirheumatic drugs; PALACE, Psoriatic Arthritis Long-Term Assessment of Clinical Efficacy.
References: 1. Data on file, Celgene Corporation. 2. Wells AF, Edwards CJ, Kivitz AJ, et al. Apremilast Monotherapy as the First Systemic Treatment in DMARD-Naïve Patients With Psoriatic Arthritis: 3-Year Treatment Results. Presented at: the Annual European Congress of Rheumatology EULAR 2016; 8–11 June 2016; London, UK. 3. OTEZLA Summary of Product Characteristics. Celgene Europe, Ltd. Stockley Park, Uxbridge, UK.
Please choose a country